Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1518 studies found for:    alzheimer's
Show Display Options
Download search resultsDownload the search results for:
alzheimer's (1518 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Completed
Has Results
A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease
Condition: Alzheimer´s Disease
Interventions: Biological: Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg;   Biological: Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg;   Biological: Placebo solution: Human Albumin 0.25% - 4 mL/kg;   Biological: Placebo solution: Human Albumin 0.25% - 2 mL/kg
2 Active, not recruiting Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training
Condition: Alzheimer's Disease
Interventions: Behavioral: Individualized management of AD including caregiver training;   Drug: Memantine
3 Recruiting A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease
Conditions: Alzheimer's Disease;   Dementia
Interventions: Drug: Drug: NIC5-15;   Drug: Placebo
4 Completed
Has Results
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44
Condition: Alzheimer's Disease
Interventions: Drug: Rivastigmine 4.6 mg/24 h (5 cm^2);   Drug: Rivastigmine 9.5 mg/24 h (10 cm^2);   Drug: Rivastigmine 13.3 mg/24 h (15 cm^2);   Drug: Placebo
5 Completed
Has Results
Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo
Condition: Alzheimer's Disease
Interventions: Drug: LY450139;   Drug: Placebo
6 Recruiting Alzheimer's Prevention Registry
Conditions: Alzheimer's Disease;   Dementia
Intervention:
7 Completed
Has Results
Evaluation of the Efficacy of Varenicline on Cognition, Safety, Tolerability and Pharmacokinetics in Subjects With Mild-to-Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: Varenicline;   Drug: Placebo
8 Completed Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
Condition: Alzheimer's Disease
Interventions: Drug: Donepezil;   Drug: AZD3480
9 Completed
Has Results
A Pilot Trial of Interferon Beta-1a in Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: Interferon beta-1a;   Drug: Placebo
10 Recruiting Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: TRx0237 200 mg/day;   Drug: Placebo
11 Withdrawn Functional Magnetic Resonance Imaging - Synthetic Aperture Magnetometry (fMRI-SAM) and Alzheimer's Disease
Condition: Alzheimer's Disease
Intervention: Procedure: fMRI to detect MCI patients who will convert to Alzheimer's disease
12 Active, not recruiting Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Genetic: CERE-110: Adeno-Associated Virus Delivery of NGF;   Procedure: Placebo Surgery
13 Active, not recruiting Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: TRx0237 150 mg/day;   Drug: TRx0237 250 mg/day;   Drug: Placebo
14 Recruiting Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.
Conditions: Alzheimers Disease;   Dementia;   Alzheimers Disease, Familial
Interventions: Drug: Gantenerumab;   Drug: Solanezumab;   Drug: Matching Placebo (Gantenerumab);   Drug: Matching Placebo (Solanezumab)
15 Completed
Has Results
Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline
Condition: Alzheimer Disease
Interventions: Drug: Rivastigmine 5 cm^2;   Drug: Rivastigmine 10 cm^2;   Drug: Rivastigmine 15 cm^2;   Drug: Placebo to 15 cm^2 patch;   Drug: Placebo to 10 cm^2 patch
16 Completed
Has Results
ELND005 in Patients With Mild to Moderate Alzheimer's Disease
Condition: Alzheimer Disease
Interventions: Drug: Placebo Control;   Drug: ELND005
17 Completed
Has Results
A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: Rivastigmine Patch;   Drug: Rivastigmine Capsules;   Drug: Placebo to Rivastigmine patch;   Drug: Placebo to Rivastigmine capsules
18 Completed
Has Results
Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease
Conditions: Mild Cognitive Impairment;   Alzheimer's Disease
Intervention: Drug: Flutemetamol (18F) Injection
19 Completed
Has Results
Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: Rivastigmine transdermal patch;   Drug: Placebo
20 Completed Improved Diagnosis of Alzheimer's Disease Using Magnetoencephalography (MEG)
Condition: Alzheimer's Disease
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years